AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-18T00:26:00Z
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Mon 21 Oct 24, 04:39 PMCatalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Mon 21 Oct 24, 11:00 AMConsumer groups ask FTC to block Novo Holdings-Catalent deal
Thu 17 Oct 24, 06:03 PMCatalent Stock Flat Following the Sell Agreement With Ardena
Wed 16 Oct 24, 05:15 PMCatalent to sell New Jersey facility
Mon 14 Oct 24, 10:39 AMCatalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Mon 14 Oct 24, 10:00 AMUS Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
Thu 10 Oct 24, 12:03 PMThe Zacks Analyst Blog Highlights AppLovin, Duolingo, Paramount, Twilio and Catalent
Fri 04 Oct 24, 10:02 AMMore Interest Rate Cuts Ahead: 5 Growth Stocks to Benefit
Thu 03 Oct 24, 06:00 PMTAK or CTLT: Which Is the Better Value Stock Right Now?
Thu 03 Oct 24, 03:40 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -315.00000M | 605.00M | 715.00M | 260.40M | 160.30M |
| Minority interest | - | - | - | - | -5.40000M |
| Net income | -232.00000M | 519.00M | 585.00M | 220.70M | 137.40M |
| Selling general administrative | 884.00M | 884.00M | 687.00M | 577.90M | 512.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1060.00M | 1640.00M | 1352.00M | 983.30M | 805.10M |
| Reconciled depreciation | - | 378.00M | 289.00M | 253.70M | 228.60M |
| Ebit | -137.00000M | 349.00M | 354.00M | 143.80M | 61.80M |
| Ebitda | 79.00M | 727.00M | 643.00M | 397.50M | 290.40M |
| Depreciation and amortization | 216.00M | 378.00M | 289.00M | 253.70M | 228.60M |
| Non operating income net other | -28.00000M | -28.00000M | -3.00000M | - | -2.70000M |
| Operating income | -137.00000M | 349.00M | 354.00M | 143.80M | 61.80M |
| Other operating expenses | 4203.00M | 4073.00M | 3352.00M | 2688.90M | 2224.90M |
| Interest expense | 184.00M | 123.00M | 110.00M | 126.10M | 110.90M |
| Tax provision | -83.00000M | 86.00M | 130.00M | 39.70M | 22.90M |
| Interest income | - | - | - | - | 110.40M |
| Net interest income | -184.00000M | -127.00000M | -110.00000M | -126.10000M | -126.70000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | 19.20M |
| Other items | - | - | - | - | - |
| Income tax expense | -83.00000M | 86.00M | 130.00M | 39.70M | 22.90M |
| Total revenue | 4276.00M | 4828.00M | 3998.00M | 3094.30M | 2518.00M |
| Total operating expenses | 987.00M | 885.00M | 706.00M | 577.90M | 512.00M |
| Cost of revenue | 3216.00M | 3188.00M | 2646.00M | 2111.00M | 1712.90M |
| Total other income expense net | -204.00000M | 256.00M | 361.00M | 116.60M | 98.50M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 499.00M | 519.00M | 585.00M | 220.70M | 183.20M |
| Net income applicable to common shares | 483.00M | 503.00M | 529.00M | 173.00M | 137.40M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 10782.00M | 10507.00M | 9112.00M | 7776.50M | 6184.00M |
| Intangible assets | 980.00M | 1060.00M | 817.00M | 888.70M | 930.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 658.00M | 70.00M | 376.00M | 177.90M | 76.80M |
| Total liab | 6147.00M | 5712.00M | 5197.00M | 4877.70M | 4502.40M |
| Total stockholder equity | 4635.00M | 4795.00M | 3915.00M | 2898.80M | 1681.60M |
| Deferred long term liab | 197.00M | 202.00M | 164.00M | 2.40M | 74.40M |
| Other current liab | 544.00M | 435.00M | 431.00M | 308.30M | 183.20M |
| Common stock | 2.00M | 2.00M | 2.00M | 1.60M | 1.50M |
| Capital stock | - | 2.00M | 361.00M | 608.20M | 1.50M |
| Retained earnings | 262.00M | 538.00M | 25.00M | -535.20000M | -723.40000M |
| Other liab | 327.00M | 469.00M | 399.00M | 340.90M | 342.30M |
| Good will | 3039.00M | 3006.00M | 2519.00M | 2470.60M | 2220.90M |
| Other assets | 4404.00M | 4431.00M | 210.00M | 122.00M | 99.80M |
| Cash | 280.00M | 449.00M | 896.00M | 953.20M | 345.40M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1507.00M | 1072.00M | 1196.00M | 893.20M | 670.70M |
| Current deferred revenue | - | 185.00M | 305.00M | 191.00M | 155.20M |
| Net debt | 4569.00M | 3753.00M | 2345.00M | 2064.80M | 2613.90M |
| Short term debt | 536.00M | 31.00M | 75.00M | 72.90M | 76.50M |
| Short long term debt | 536.00M | 31.00M | 75.00M | 72.90M | 76.50M |
| Short long term debt total | 4849.00M | 4202.00M | 3241.00M | 3018.00M | 2959.30M |
| Other stockholder equity | 4701.00M | -5858.00000M | 3846.00M | 3212.10M | 2150.80M |
| Property plant equipment | 3127.00M | 3127.00M | 2524.00M | 2002.20M | 1536.70M |
| Total current assets | 2679.00M | 2916.00M | 2918.00M | 2293.00M | 1395.80M |
| Long term investments | - | 33.00M | 38.00M | - | - |
| Net tangible assets | 709.00M | 729.00M | 938.00M | -460.50000M | -863.50000M |
| Short term investments | 89.00M | 89.00M | 71.00M | - | - |
| Net receivables | 977.00M | 1051.00M | 1012.00M | 838.10M | 716.40M |
| Long term debt | 4171.00M | 4171.00M | 3166.00M | 2945.10M | 2882.80M |
| Inventory | 764.00M | 702.00M | 563.00M | 323.80M | 257.20M |
| Accounts payable | 427.00M | 421.00M | 385.00M | 321.00M | 255.80M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -354.00000M | -394.00000M | -317.00000M | -386.30000M | -353.90000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 2.00M | 2.00M | 2.00M | 1.60M | 1.50M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 518.00M | 538.00M | 25.00M | - | -723.40000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4404.00M | 316.00M | 230.00M | 3582.70M | 3251.50M |
| Deferred long term asset charges | - | - | - | - | 38.60M |
| Non current assets total | 8103.00M | 7591.00M | 6194.00M | 5483.50M | 4788.20M |
| Capital lease obligations | - | 14.00M | 16.00M | - | - |
| Long term debt total | 4171.00M | 4171.00M | 3166.00M | - | 2882.80M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -22.00000M | -22.00000M | -649.00000M | -827.50000M | 1.80M |
| Change to liabilities | 37.00M | 37.00M | 50.00M | 72.20M | 36.20M |
| Total cashflows from investing activities | -1884.00000M | -1884.00000M | -649.00000M | -827.50000M | -1510.40000M |
| Net borrowings | 1007.00M | 1007.00M | 80.00M | 48.30M | 124.20M |
| Total cash from financing activities | 521.00M | 1031.00M | 142.00M | 1001.70M | 1201.40M |
| Change to operating activities | - | -448.00000M | -36.00000M | 33.80M | -43.60000M |
| Net income | -256.00000M | 519.00M | 585.00M | 220.70M | 137.40M |
| Change in cash | -169.00000M | -447.00000M | -57.00000M | 607.80M | -64.80000M |
| Begin period cash flow | 449.00M | 896.00M | 953.00M | 345.40M | 410.20M |
| End period cash flow | 280.00M | 449.00M | 896.00M | 953.20M | 345.40M |
| Total cash from operating activities | 261.00M | 439.00M | 433.00M | 440.30M | 247.70M |
| Issuance of capital stock | - | 0.00000M | 82.00M | 1046.50M | 1091.80M |
| Depreciation | 422.00M | 378.00M | 289.00M | 253.70M | 228.60M |
| Other cashflows from investing activities | -1202.00000M | -1196.00000M | -147.00000M | - | -1290.50000M |
| Dividends paid | 4.00M | -4.00000M | -22.00000M | -36.20000M | 36.20M |
| Change to inventory | -192.00000M | -128.00000M | -260.00000M | -76.40000M | -34.00000M |
| Change to account receivables | 53.00M | -73.00000M | -186.00000M | -150.90000M | -118.90000M |
| Sale purchase of stock | 26.00M | 26.00M | 202.00M | 909.10M | 1091.80M |
| Other cashflows from financing activities | 751.00M | 751.00M | -53.00000M | -56.90000M | 2054.60M |
| Change to netincome | 121.00M | 126.00M | -79.00000M | 74.80M | 9.90M |
| Capital expenditures | 583.00M | 660.00M | 686.00M | 465.80M | 218.10M |
| Change receivables | -73.00000M | -73.00000M | -186.00000M | - | -118.90000M |
| Cash flows other operating | -399.00000M | -424.00000M | 16.00M | - | -16.90000M |
| Exchange rate changes | - | - | 17.00M | - | -3.50000M |
| Cash and cash equivalents changes | -414.00000M | -414.00000M | -57.00000M | - | -64.80000M |
| Change in working capital | -160.00000M | -612.00000M | -432.00000M | -121.30000M | -160.30000M |
| Stock based compensation | 35.00M | 54.00M | 51.00M | 48.10M | 33.30M |
| Other non cash items | 347.00M | 86.00M | -124.00000M | 36.70M | 23.80M |
| Free cash flow | -322.00000M | -221.00000M | -253.00000M | -25.50000M | 29.60M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CTLT Catalent Inc |
0.02 0.03% | 63.50 | - | 51.81 | 1.86 | 2.02 | 2.96 | -25.2365 |
| ZTS Zoetis Inc |
-2.975 1.78% | 164.03 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.12 0.42% | 28.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-1.925 1.33% | 142.50 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.07 0.53% | 13.04 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
14 Schoolhouse Road, Somerset, NJ, United States, 08873
| Name | Title | Year Born |
|---|---|---|
| Mr. John R. Chiminski | Exec. Chair of the Board | 1964 |
| Mr. Alessandro Maselli | CEO & Director | 1972 |
| Mr. Thomas P. Castellano | Sr. VP & CFO | 1980 |
| Mr. Steven L. Fasman Esq. | Exec. VP, Corp. Sec. & Chief Admin. Officer | 1963 |
| Dr. Aristippos Gennadios Ph.D. | Group Pres of Pharma & Consumer Health Segment | 1966 |
| Mr. Ricky Hopson | Pres & Division Head for Clinical Devel. and Supply | 1976 |
| Ms. Karen Murphy Santiago | VP & Chief Accounting Office | 1971 |
| Mr. Julien Meissonnier | VP & Chief Scientific Officer | NA |
| Mr. Charles Lickfold | Sr. VP & Chief Information Officer | 1974 |
| Mr. Paul Surdez | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...